• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

左心室肌切开术和心肌切除术治疗梗阻性肥厚型心肌病的长期结果

Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy.

作者信息

Robbins R C, Stinson E B

机构信息

Falk Cardiovascular Research Center, Stanford University School of Medicine, CA 94305-5247, USA.

出版信息

J Thorac Cardiovasc Surg. 1996 Mar;111(3):586-94. doi: 10.1016/s0022-5223(96)70310-0.

DOI:10.1016/s0022-5223(96)70310-0
PMID:8601973
Abstract

A retrospective analysis of patients with hypertrophic obstructive cardiomyopathy treated by left ventricular myotomy and myectomy from 1972 to 1994 is reported. There were 158 patients (81 male and 77 female) with a mean age of 50.2(+/-17.2) years (range 12 to 80 years). One hundred nine patients (69%) were 60 years of age or younger, and 49 patients (31%) were older than 60 years. The overall mean follow-up period was 6.1(+/-4.8) years (range 0.1 to 19.3 years) and was 94% complete with a cumulative total of 956 patient-years. Preoperative exertional dyspnea was present in 84%, chest pain in 70%, presyncope in 54%, syncope in 31%, and cardiac arrest in 5% of patients. Preoperative cardiac catheterization was done in 150 patients, with mitral regurgitation detected in 104 patients (67%). The average maximal provocable left ventricular outflow tract gradient was 118 (+/-46) mm Hg (range 25 to 250 mm Hg). The average preoperative echocardiographic gradient at rest was 64 mm Hg, 20 mm Hg in the early postoperative period and 10 mm Hg in the late postoperative period. The mean septal thickness was 2.2 (+/-0.6) cm, 1.9 (+/-0.7) cm in the early postoperative period (p < 0.05 vs preoperative) and 1.7 (+/- 0.5) cm in the late postoperative period (p < 0.05 vs preoperative). The overall 30-day operative mortality rate was 3.2% (5/158), and 0% for 109 patients 60 years of age or younger. Causes of death included myocardial infarction and left ventricular free wall rupture, myocardial failure from septal perforation, sepsis, cerebrovascular accident caused by thromboembolism, and delayed cardiac tamponade in one patient each. Concomitant coronary artery bypass grafting was performed in 22 patients (19.3% of patients > or = to 40 years of age) and mitral valve replacement in 5 patients (3.2%). One hundred nine patients (69%) are alive, 10 patients (6.3%) were lost to follow-up, and 39 patients died (24.7%), including operative deaths). Actuarial survivals at 1, 5, 10, and 15 years were 92.4% +/- 2.2%, 85.4% +/- 3.1%, 71.5 +/- 4.6%, and 46% +/- 9%, respectively. The overall linearized death rate for discharged patients was 1.9%/pt-yr, and for cardiac related deaths it was 1.7%/pt-yr. Thirty-nine (36%) of the 109 survivors received beta-adrenergic blockers, and 30 (28%) received calcium channel blockers. Ninety-four patients had improvement in New York Heart Association functional class, 10 had improvement in symptoms but not in functional class, and 5 had no improvement in functional class or symptoms. Neither preoperative hemodynamic values nor routine echocardiographic measurements significantly correlated with quality of postoperative results. Left ventricular myotomy and myectomy is a safe and reproducibly effective operative treatment for medically refractory hypertrophic obstructive cardiomyopathy, especially for patients 60 years of age or younger. Improvement in functional class and symptoms can be expected in nearly all patients 60 years of age or younger. Improvement in functional class and symptoms can be expected in nearly all patients. The results of myotomy and myectomy serve as a standard for comparison with other interventions for medically refractory cardiomyopathy.

摘要

本文报道了1972年至1994年间接受左心室肌切开术和心肌切除术治疗的肥厚性梗阻性心肌病患者的回顾性分析。共有158例患者(男性81例,女性77例),平均年龄50.2(±17.2)岁(范围12至80岁)。109例患者(69%)年龄在60岁及以下,49例患者(31%)年龄大于60岁。总体平均随访期为6.1(±4.8)年(范围0.1至19.3年),随访完成率为94%,累计患者年数为956。84%的患者术前有劳力性呼吸困难,70%有胸痛,54%有先兆晕厥,31%有晕厥,5%有心脏骤停。150例患者术前行心导管检查,104例患者(67%)检测到二尖瓣反流。平均最大可诱发左心室流出道压差为118(±46)mmHg(范围25至250mmHg)。术前静息时超声心动图平均压差为64mmHg,术后早期为20mmHg,术后晚期为10mmHg。平均室间隔厚度为2.2(±0.6)cm,术后早期为1.9(±0.7)cm(与术前相比p<0.05),术后晚期为1.7(±0.5)cm(与术前相比p<0.05)。总体30天手术死亡率为3.2%(5/158),60岁及以下的109例患者死亡率为0%。死亡原因包括心肌梗死和左心室游离壁破裂、室间隔穿孔导致的心肌衰竭、败血症、血栓栓塞引起的脑血管意外以及1例患者的迟发性心脏压塞。22例患者(≥40岁患者的19.3%)同时进行了冠状动脉旁路移植术,5例患者(3.2%)进行了二尖瓣置换术。109例患者(69%)存活,10例患者(6.3%)失访,39例患者死亡(24.7%,包括手术死亡)。1年、5年、10年和15年的精算生存率分别为92.4%±2.2%、85.4%±3.1%、71.5±4.6%和46%±9%。出院患者的总体线性化死亡率为1.9%/患者年,心脏相关死亡的线性化死亡率为1.7%/患者年。109例幸存者中有39例(36%)接受了β受体阻滞剂治疗,30例(28%)接受了钙通道阻滞剂治疗。94例患者纽约心脏协会功能分级改善,10例患者症状改善但功能分级未改善,5例患者功能分级和症状均未改善。术前血流动力学值和常规超声心动图测量均与术后结果质量无显著相关性。左心室肌切开术和心肌切除术是治疗药物难治性肥厚性梗阻性心肌病的一种安全且可重复有效的手术治疗方法,尤其适用于60岁及以下的患者。几乎所有60岁及以下的患者都有望改善功能分级和症状。几乎所有患者都有望改善功能分级和症状。肌切开术和心肌切除术的结果可作为与其他治疗药物难治性心肌病的干预措施进行比较的标准。

相似文献

1
Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy.左心室肌切开术和心肌切除术治疗梗阻性肥厚型心肌病的长期结果
J Thorac Cardiovasc Surg. 1996 Mar;111(3):586-94. doi: 10.1016/s0022-5223(96)70310-0.
2
Septal myectomy in hypertrophic obstructive cardiomyopathy: late results with stress echocardiography.肥厚型梗阻性心肌病的室间隔心肌切除术:负荷超声心动图的远期结果
Ann Thorac Surg. 1997 Sep;64(3):739-45. doi: 10.1016/s0003-4975(97)00633-4.
3
Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results.肥厚性梗阻性心肌病的外科治疗。早期和晚期结果。
J Thorac Cardiovasc Surg. 1995 Jul;110(1):195-206; discussion 206-8. doi: 10.1016/s0022-5223(05)80026-1.
4
Relationship between left ventricular mass, wall thickness, and survival after subaortic septal myectomy for hypertrophic obstructive cardiomyopathy.主动脉瓣下室间隔心肌切除术治疗肥厚型梗阻性心肌病患者左心室质量、室壁厚度与生存的关系。
J Thorac Cardiovasc Surg. 2011 Feb;141(2):439-43. doi: 10.1016/j.jtcvs.2010.04.046. Epub 2010 Sep 15.
5
The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy. Experience over 15 years.肥厚性梗阻性心肌病的外科治疗结果。15年的经验。
J Thorac Cardiovasc Surg. 1989 May;97(5):666-74.
6
The surgical management of hypertrophic obstructive cardiomyopathy with the concomitant mitral valve abnormalities.肥厚性梗阻性心肌病合并二尖瓣异常的外科治疗
Interact Cardiovasc Thorac Surg. 2015 Dec;21(6):722-6. doi: 10.1093/icvts/ivv257. Epub 2015 Sep 15.
7
The results of operation in patients with hypertrophic cardiomyopathy and pulmonary hypertension.肥厚型心肌病合并肺动脉高压患者的手术结果。
J Thorac Cardiovasc Surg. 1990 Sep;100(3):343-51; discussion 352.
8
Septal myectomy for obstructive hypertrophic cardiomyopathy in pediatric patients: early and late results.小儿梗阻性肥厚型心肌病的室间隔心肌切除术:早期和晚期结果
Ann Thorac Surg. 2005 Oct;80(4):1424-9; discussion 1429-30. doi: 10.1016/j.athoracsur.2005.03.109.
9
Extended myectomy for hypertrophic obstructive cardiomyopathy.肥厚性梗阻性心肌病的扩大性心肌切除术
Heart Surg Forum. 2012 Oct;15(5):E251-6. doi: 10.1532/HSF98.20111185.
10
Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy.肥厚性梗阻性心肌病经室间隔心肌切除术后的长期随访
Ann Thorac Surg. 1998 May;65(5):1207-14. doi: 10.1016/s0003-4975(98)00187-8.

引用本文的文献

1
Mid-term results of the floating stitch for systolic anterior motion in hypertrophic obstructive cardiomyopathy.肥厚型梗阻性心肌病收缩期前向运动的漂浮缝合术中期结果
Gen Thorac Cardiovasc Surg. 2025 Jun 12. doi: 10.1007/s11748-025-02167-6.
2
Mexican guidelines 2024 for the diagnosis and treatment of hypertrophic cardiomyopathy.《2024年墨西哥肥厚型心肌病诊断与治疗指南》
Arch Cardiol Mex. 2024;94(Supl 4):1-75. doi: 10.24875/ACM.M25000098.
3
Three-Dimensional Heart Modeling of Hypertrophic Obstructive Cardiomyopathy for In Situ Patient-Specific Simulation to Optimize Septal Myectomy.
肥厚型梗阻性心肌病的三维心脏建模用于原位患者特异性模拟以优化室间隔心肌切除术
Innovations (Phila). 2024 Sep-Oct;19(5):532-540. doi: 10.1177/15569845241273538. Epub 2024 Sep 2.
4
Inherited Arrhythmias in the Pediatric Population: An Updated Overview.儿科人群遗传性心律失常:最新概述。
Medicina (Kaunas). 2024 Jan 3;60(1):94. doi: 10.3390/medicina60010094.
5
Risk stratification for sudden cardiac death after septal myectomy.肥厚性梗阻型心肌病患者行室间隔心肌切除术后心脏性猝死的风险分层
J Cardiol Cases. 2011 Jan 13;3(2):e65-e67. doi: 10.1016/j.jccase.2010.12.002. eCollection 2011 Apr.
6
Endoscopic Port Access left ventricle outflow tract resection and atrioventricular valve surgery.内镜端口入路左心室流出道切除术及房室瓣手术。
J Vis Surg. 2018 May 11;4:100. doi: 10.21037/jovs.2018.05.01. eCollection 2018.
7
Hypertrophic Cardiomyopathy-Past, Present and Future.肥厚型心肌病——过去、现在与未来
J Clin Med. 2017 Dec 12;6(12):118. doi: 10.3390/jcm6120118.
8
Short atrioventricular delay pacing therapy in young and old patients with hypertrophic obstructive cardiomyopathy: good long-term results and a low need for reinterventions.短房室延迟起搏治疗肥厚型梗阻性心肌病的年轻和老年患者:良好的长期结果和较低的再干预需求。
Europace. 2018 Oct 1;20(10):1683-1691. doi: 10.1093/europace/eux331.
9
Long-term outcome of simultaneous septal myectomy and anterior mitral leaflet retention plasty in hypertrophic obstructive cardiomyopathy: the Berlin experience.肥厚型梗阻性心肌病同期室间隔心肌切除术和二尖瓣前叶保留成形术的长期疗效:柏林经验
Ann Cardiothorac Surg. 2017 Jul;6(4):343-352. doi: 10.21037/acs.2017.03.08.
10
Surgery for hypertrophic cardiomyopathy.肥厚型心肌病的外科治疗。
Biophys Rev. 2015 Mar;7(1):117-125. doi: 10.1007/s12551-014-0153-3. Epub 2015 Jan 10.